Louise Kooij's most recent trade in NewAmsterdam Pharma Company NV was a trade of 18,073 Ordinary Shares done at an average price of $25.1 . Disclosure was reported to the exchange on Sept. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.09 per share. | 03 Sep 2025 | 18,073 | 15,000 | - | 25.1 | 453,452 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 18,073 | 0 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 18,073 | 33,073 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 24.86 per share. | 25 Aug 2025 | 8,269 | 15,000 | - | 24.9 | 205,567 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 8,269 | 23,269 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 8,269 | 8,269 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 8,269 | 0 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 150,000 | 165,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 150,000 | 18,073 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.37 per share. | 04 Mar 2025 | 150,000 | 15,000 | - | 20.4 | 3,055,500 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 15,000 | 15,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 80,000 | 80,000 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2024 | 45,000 | 45,000 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2024 | 45,000 | 168,073 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 15.72 per share. | 27 Sep 2024 | 45,000 | 0 | - | 15.7 | 707,400 | Ordinary Shares |
| NewAmsterdam Pharma Company NV | Louise Kooij | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 150,494 | 150,494 | - | - | Option (right to buy) |